GlassScriptPhysician profile
Brian M Go
NPI 1851397152
$4,825.30
in general payments reported to CMS, 2019-2025
33 companies · $989 in 2025
The $989 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,694 · 2020: $143 · 2021: $285 · 2022: $130 · 2023: $686 · 2024: $898 · 2025: $989.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,574.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,574.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $1,247.80 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $487.35 | 2020-2025 | Lifevest |
| Pfizer INC. | $346.92 | 2023-2025 | |
| Irhythm Technologies, INC. | $307.41 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Novartis Pharmaceuticals Corporation | $205.28 | 2019-2025 | |
| Boston Scientific Corporation | $203.07 | 2021-2025 | Bodyguardian, Avvigo Guidance System |
| Astrazeneca Pharmaceuticals LP | $195.23 | 2019-2025 | Farxiga, Wainua |
| Abiomed | $151.62 | 2020-2024 | Impella |
| Siemens Medical Solutions USA, INC. | $146.75 | 2019 | |
| Recor Medical INC | $133.06 | 2025 | Paradise Ultrasound Renal Denervation System |
| Shockwave Medical, INC | $121.05 | 2021-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Merck Sharp & Dohme LLC | $120.85 | 2023-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $117.00 | 2024-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $106.02 | 2019-2024 | Xarelto |
| Edwards Lifesciences Corporation | $103.27 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $97.24 | 2023-2025 | Extended Holter, Coronary Other |
| Heartflow, INC. | $89.00 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.70 | 2025 | Jardiance |
| Braemar Manufacturing, LLC | $65.38 | 2019 | |
| Sanofi-Aventis U.S. LLC | $55.70 | 2023-2024 | |
| Amgen INC. | $53.88 | 2024-2025 | Repatha, Repatha |
| Alnylam Pharmaceuticals INC. | $51.34 | 2025 | Amvuttra |
| Bridgebio Pharma, INC. | $50.36 | 2025 | Attruby |
| Novo Nordisk INC | $46.06 | 2025 | Wegovy |
| Esperion Therapeutics, INC. | $43.97 | 2023-2024 | Nexletol |
| Abbott Laboratories | $43.47 | 2019 | |
| Celgene Corporation | $37.65 | 2023-2024 | Camzyos |
| Lexicon Pharmaceuticals, INC. | $37.07 | 2023 | Inpefa |
| Genzyme Corporation | $27.39 | 2024 | |
| Cardiva Medical, INC. | $25.17 | 2023 | Cardiva Vascade 6/7f Vcs |
| Zoll Circulation INC | $20.88 | 2022 | |
| Nuwellis, INC. | $12.36 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Go listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.